كو-تريموكسازول
|
كو-تريموكسازول {{{English
| |
| مجموع | |
| الاسم النظامي (أيوپاك) | |
| Trimethoprim | Dihydrofolate reductase inhibitor (20%) |
| Sulfamethoxazole | Sulfonamide antibiotic (80%) |
| المعينات Identifiers | |
| رقم CAS | |
| كود ATC | J01 |
| PubChem | |
| بيانات كيميائية | |
| الصيغة | ? |
| كتلة جزيئية | ? |
| بيانات الحركية الدوائية Pharmacokinetic | |
| التوافر الحيوي | ? |
| الأيض | ? |
| عمر النصف | ? |
| اخراج | ? |
| اعتبارات علاجية | |
| فئة السلامة أثناء الحمل |
C(استراليا) C(الولايات المتحدة) |
| الوضع القانوني |
(الولايات المتحدة) |
| المسارات | Oral |
كو-تراىموكسازول كو-تراىموكسازول يختصر ب SXT, TMP-SMX, TMP-SMZ or TMP-sulfa ,هودواء سلفوناميد. Co-trimoxazole (abbreviated SXT, TMP-SMX, TMP-SMZ or TMP-sulfa) is a sulfonamide antibacterial combination of trimethoprim and sulfamethoxazole, in the ratio of 1 to 5, used in the treatment of a variety of bacterial infections. The name co-trimoxazole is the British Approved Name, and has been marketed worldwide under many trade names including Septra (GSK), Bactrim (Roche), and various generic preparations. Sources differ as to whether co-trimoxazole usually is bactericidal or bacteriostatic.
التأثير المعضض(تأثير مقوى)
Co-trimoxazole exhibits a theoretical, although perhaps not a clinical,
الاستخدامات السريرية
. Along with its associated greater incidence of adverse effects including allergic responses (see below), its widespread use has been restricted in many countries to very specific circumstances where its improved efficacy is demonstrated. It may be effective in a variety of upper and lower respiratory tract infections, renal and urinary tract infections, gastrointestinal tract infections, skin and wound infections, septicaemias and other infections caused by sensitive organisms.
Specific indications for its use include:
البكتيريا
- infections caused by Listeria monocytogenes, Nocardia spp., Stenotrophomonas maltophilia (Zanthomonas maltophilia)
- Infections caused by Staphylcoccus saprophyticus and patient is presenting with urinary tract infection or cystitis
- melioidosis
- shigellosis
- Whipple's disease
الكائنات الأولية
غير محدد
- traveller's diarrhea
This article needs additional citations for verification. (September 2008)
|
الأمان
Thus the current British Committee on Safety of Medicines (CSM) guidelines recommend limiting its use to:[بحاجة لمصدر]
- Pneumocystis pneumonia
- Toxoplasmosis and nocardiosis
- acute exacerbations of chronic bronchitis and infections of the urinary tract where there is good rationale for use
- acute otitis media in children where there is good rationale
المراجع
- Rossi S, editor. Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook; 2004. ISBN 0-9578521-4-2.
- British National Formulary, 51st edition (April 20, 2006). London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2006. ISBN 0853696683
- briandeer.com Newspaper campaign over adverse events; 1994-
التذييلات
-
^ Brumfitt W, Hamilton-Miller JM (1994). "Limitations of and indications for the use of co-trimoxazole". J Chemother. 6 (1): 3–11. PMID 8071675. Unknown parameter
|month=ignored (help) -
^ Brumfitt W, Hamilton-Miller JM (1993). "Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines". J Chemother. 5 (6): 465–9. PMID 8195839. Unknown parameter
|month=ignored (help) -
^ "Co-trimoxazole use restricted". Drug Ther Bull. 33 (12): 92–3. 1995. doi:10.1136/dtb.1995.331292. PMID 8777892. Unknown parameter
|month=ignored (help)
